Jurgens, E. M., Firestone, R. S., Chaudhari, J., Hosszu, K., Devlin, S. M., Shah, U. A., Landa, J., McAvoy, D. P., Lesokhin, A. M., Korde, N., Hassoun, H., Tan, C. R., Hultcrantz, M., Shah, G. L., Landau, H. J., Chung, D. J., Scordo, M., Eren, O. C., Dogan, A., Giralt, S. A., Park, J. H., Rivière, I., Brentjens, R. J., Smith, E. L., Wang, X., Usmani, S. Z., Mailankody, S. (2025). Phase I Trial of MCARH109, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01785